Key result
Severe COVID-19 pneumonia in hypertensive patients is linked to a ~29% drop in L-arginine concentration.
Cross-Sectional (n=66)
No
Effect estimate: 28.9% decrease
Absolute Event Rate: 25.92% vs 36.45%
p-value: p=<0.05
In patients with arterial hypertension, severe COVID-19 pneumonia is associated with significant L-arginine depletion and increased arginase activity, suggesting profound endothelial dysfunction.
L-arginine depletion may mark endothelial dysfunction in hypertensive severe COVID-19; hypothesis-generating and requires prospective trials before any therapeutic consideration.
Активність NO-синтази й аргінази та вміст L-аргініну в лімфоцитах периферичної крові пацієнтів з артеріальною гіпертензією в поєднанні з COVID-19-пневмонією
No takes yet. Share an insight, caveat, or question.
O. Y. Sklyarova (2022) conducted a cross-sectional in Arterial hypertension with COVID-19 pneumonia (n=66). Severe COVID-19 pneumonia vs. Mild COVID-19 pneumonia and healthy controls was evaluated on L-arginine concentration (µmol/L) (28.9% decrease, p=<0.05). Severe COVID-19 pneumonia in patients with arterial hypertension was associated with a 28.9% decrease in L-arginine concentration compared to healthy controls and a 37.5% increase in arginase activity compared to mild COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: